These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 788353)

  • 1. [Intravenous infusions in the treatment of arterial occlusive diseases from the surgical point of view].
    Hugeneck J
    Wien Med Wochenschr; 1976 Sep; 126(38):542-4. PubMed ID: 788353
    [No Abstract]   [Full Text] [Related]  

  • 2. [Action of raubasine (new formulation) in arterial occlusive diseases (author's transl)].
    Schütz RM; Teufel W; Glocke M
    Med Klin; 1976 Sep; 71(39):1605-10. PubMed ID: 790128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intravenous infusion of Naftidrofuryl in the treatment of arterial diseases of the limbs. Clinical and functional study].
    Schmidt C; Royer RJ; Kissel P
    Therapie; 1974; 29(6):915-23. PubMed ID: 4618388
    [No Abstract]   [Full Text] [Related]  

  • 4. [Reaction of the blood circulation in the extremities with intravenous Raubasin infusions].
    Schütz RM; Kramer H
    Med Welt; 1971 Apr; 14():554-9. PubMed ID: 5551941
    [No Abstract]   [Full Text] [Related]  

  • 5. [Observations during ambulatory therapy of functional and organic circulatory disorders with Defluina].
    Brüning G
    Med Welt; 1975 Sep; 26(38):1737-41. PubMed ID: 810634
    [No Abstract]   [Full Text] [Related]  

  • 6. Pilot study of the effects of taprostene (CG 4203) in patients with advanced peripheral arterial disease.
    Darius H; Kopp H; Mulfinger A; Spielberger M; Todt M; Schuster CJ; Meyer J
    Prog Clin Biol Res; 1989; 301():417-21. PubMed ID: 2508112
    [No Abstract]   [Full Text] [Related]  

  • 7. Intravenous prostavasin--therapy in peripheral arterial occlusive disease in Fontaine's stages III and IV. Early and late results of a screening study.
    Heidrich H; Meuche C; Ranft J; Rummel S; Peters A
    Prog Clin Biol Res; 1989; 301():411-6. PubMed ID: 2678131
    [No Abstract]   [Full Text] [Related]  

  • 8. [Parameters for the measurement of long-term effects of an orally administered drug in organic and functional circulatory disorders. Preliminary communication].
    Schuster CJ; von Ungern-Sternberg AF
    ZFA (Stuttgart); 1976 Jan; 52(2):105-10. PubMed ID: 817527
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of benfurodil hemiscucinate (Eucilat) on various hemorheologic parameters in patients with chronic peripheral obstructive arteriopathies].
    Mozzi E; Annoni F; Chiurazzi D; Rossi R; Pacini F; Martini A
    Minerva Cardioangiol; 1984 Mar; 32(3):141-9. PubMed ID: 6374499
    [No Abstract]   [Full Text] [Related]  

  • 10. [Vasoactive drugs in peripheral arterial perfusion disorders. Problems, principles and results of the determination of therapeutic efficacy].
    Heidrich H
    Dtsch Med Wochenschr; 1985 Aug; 110(31-32):1219-24. PubMed ID: 3926447
    [No Abstract]   [Full Text] [Related]  

  • 11. [Treatment of essential arterial hypertension with a thiazide-spironolactone-reserpine derivative combination].
    Klepping C; Villand J
    J Med Lyon; 1971 Sep; 52(213):1139-41. PubMed ID: 4400152
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmacological properties of reserpine 3,5,3'-triiodothyroacetate].
    Magnin A; Nicod B; Bourquin C; Magnin P
    Farmaco Sci; 1970 May; 25(5):362-85. PubMed ID: 5451640
    [No Abstract]   [Full Text] [Related]  

  • 13. Relief of chronic peripheral artery obstruction by intravenous Brinase.
    Frisch EP; Fitzgerald DE
    J Ir Med Assoc; 1973 Jun; 66(12):313-8. PubMed ID: 4721370
    [No Abstract]   [Full Text] [Related]  

  • 14. [Clinical and instrumental evaluation of patients with chronic peripheral arterial occlusive disease after prolonged administration of suloctidil].
    Gregoratti L; Redaelli G; Limido P; Ghiringhelli L
    Clin Ter; 1982 Sep; 102(6):607-19. PubMed ID: 6291844
    [No Abstract]   [Full Text] [Related]  

  • 15. [Long-term blood pressure measurements with i.v. prostaglandin E1 infusion].
    Heidrich H; Brodel C; Meuche C; Hellmann G; Ranft J
    Vasa Suppl; 1989; 27():46. PubMed ID: 2623542
    [No Abstract]   [Full Text] [Related]  

  • 16. [The cerebral blood-flow-volume in patients with sclerotic changes after treatment with raubasin (Lamuran)].
    Klemm J; Scheuring HJ
    Med Klin; 1974 May; 69(21):947-52. PubMed ID: 4602944
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical effects of intravenously administered prostaglandin E1 in patients with rest pain due to peripheral obliterative arterial disease (POAD)--a preliminary report on a placebo-controlled double-blind study.
    Diehm C; Stammler F; Hübsch-Müller C; Eckstein HH; Simini B
    Vasa Suppl; 1987; 17():52-6. PubMed ID: 3551154
    [No Abstract]   [Full Text] [Related]  

  • 18. [Reflex oximetry for evaluating blood redistribution in patients with arterial occlusive disease treated with PGE1].
    Thum J; Caspary L; Creutzig A; Alexander K
    Vasa Suppl; 1992; 35():39-41. PubMed ID: 1481056
    [No Abstract]   [Full Text] [Related]  

  • 19. [Intravenous and intra-arterial prostaglandin E1 treatment in patients with stage IIb arterial occlusive disease].
    Rudofsky G
    Vasa Suppl; 1988; 23():121-5. PubMed ID: 3206330
    [No Abstract]   [Full Text] [Related]  

  • 20. Dobutamine effect on ankle-brachial pressure index in patients with peripheral arterial occlusive disease. New noninvasive test for evaluation of peripheral circulation?
    Wysokinski WE; Spittell PC; Pellikka PA; Miller WL; Seward JB
    Int Angiol; 1998 Sep; 17(3):201-7. PubMed ID: 9821035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.